Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Yu-Ling Ma and her team's paper "Ion Channel Targeted Mechanisms of Anti-arrhythmic Chinese Herbal Medicine Xin Su Ning" has been published in Frontiers in Pharmacology.

Yu-Ling

Xin Su Ning (XSN) is a Chinese patented and certified herbal medicine used to treat premature ventricular contractions. A newly published Ma Group study demonstrates XSN’s clinical antiarrhythmic efficacy of 12 years’ use in China without adverse reactions being officially reported.

"The method used and the standard achieved bear high quality and the clinically relevant research in cellular electrophysiology on a traditional herbal medicine aimed to illuminate its clinical antiarrythmic mechanisms." - Dr Yu-Ling Ma.

XSN is only available in China, so the team's discoveries could pave the path for translating XSN to an international standard antiarrhythmic medicine through common effort.

"Due to the multi-component nature of XSN, further studies will reveal the mechanisms of the multi-targeting action of XSN that would help to advance the latest understanding that cardiac arrhythmic diseases are multifactorial and dynamic.

Further studying the action mechanisms of XSN may also help to explain how the multicomponent action helps to reduce/eliminate the adverse reactions that single chemical antiarrhythmic drugs often possess, which has led to concerns regarding the safety of antiarrhythmic drugs used clinically." - Dr Yu-Ling Ma.

The full paper can be viewed here.

Similar stories

Iron deficiency anaemia in early pregnancy increases risk of heart defects, suggests new research

In animal models, iron deficient mothers have a greatly increased risk of having offspring with congenital heart disease (CHD). The risk of CHD can be greatly reduced if the mother is given iron supplements very early in pregnancy. Additionally, embryos from a mouse model of Down Syndrome were particularly vulnerable to the effects of maternal iron deficiency, leading to a higher risk of developing severe heart defects.

New target to develop immunosuppressants

A new study from the Parekh Group has resolved a long-standing question in our understanding of intracellular Ca2+ signalling, namely how a specific type of Ca2+ channel is uniquely able to signal to the nucleus to regulate gene expression. By unravelling this mechanism, researchers have identified a new approach for developing immunosuppressant drugs.

How the kidney contributes to healthy iron levels and disease

A new study from the Lakhal-Littleton Group has addressed a long-standing gap in our understanding of systemic iron homeostasis. It provides the first formal demonstration that the hormone hepcidin controls iron reabsorption in the kidney, in a manner that impacts the body’s iron levels, under normal physiological conditions. It also demonstrates for the first time how this mechanism becomes critically important in the development of iron disorders.

New research to radically alter our understanding of synaptic development

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Being "in the zone": how waking activity controls sleep need

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.